# Genome Technology Access Center

> **NIH NIH P30** · WASHINGTON UNIVERSITY · 2021 · $330,610

## Abstract

GENOME TECHNOLOGY ACCESS CENTER (GTAC) SHARED RESOURCE: PROJECT SUMMARY
Cancer genomics is widely studied and integral to the understanding, treatment and prevention of the disease.
The Genome Technology Access Center (GTAC), a shared resource within the McDonnell Genome Institute
(MGI), is one of the largest genomic centers in the nation and provides full access to its considerable assays,
tools, technology, and expertise to Siteman Cancer Center (SCC) members to enable advances in the fight
against cancer. The common infrastructure of GTAC occupies 27,000 sq ft. of space and is staffed by
approximately 75 scientists and technicians that support both service functions and program project research.
Within this space, GTAC operates both research specific and CAP/CLIA-certified clinical genomics operations.
 As GTAC is a SCC-supported facility, the close working relationship between GTAC faculty and staff and
cancer researchers streamlines the design, execution, and interpretation of all applied genomic assays.
Furthermore, the dual nature as both a research and CAP/CLIA-certified clinical genomics service provider offers
investigators a complete translational path for their research efforts. The GTAC provides next-generation
sequencing (NGS), microarray analyses, high-throughput PCR and a number of other specialized services. NGS
microarrays and PCR are also available within the CAP/CLIA-certified laboratories.
 The combination of scale, availability, and expertise in the application of genomic technologies has enabled
a great deal of impactful research. During the project period, the GTAC (~500) and MGI (~1400) have enabled
a combined 1,900 publications as reference/acknowledgment, co-authors, or authors with a substantial
percentage dedicated to oncology research. Within this substantial body of research, key advances include the
development of a laboratory and bioinformatic workflow to support neo-epitope selection in vaccine trials, the
development of new clinical assays, including the AML exome and Myeloseq, and the invention of novel
computational platforms such as COMPBIO.

## Key facts

- **NIH application ID:** 10217006
- **Project number:** 5P30CA091842-20
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** TIMOTHY J. EBERLEIN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $330,610
- **Award type:** 5
- **Project period:** 2001-08-02 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10217006

## Citation

> US National Institutes of Health, RePORTER application 10217006, Genome Technology Access Center (5P30CA091842-20). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10217006. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*